Orlando, Florida (ots/PRNewswire) -
The World Heart Federation, Daiichi Sankyo Company, Limited (TSE:
4568) and Eli Lilly and Company (NYSE: LLY) announced today that they
have partnered to improve cardiovascular health internationally. The
organizations made the announcement at the 58th Annual Scientific
Session of the American College of Cardiology in Orlando, Florida.
An estimated 17.5 million people died from cardiovascular disease
in 2005, representing 30 percent of all global deaths, making it a
significant public health concern.(1)
Through this collaboration, Daiichi Sankyo and Lilly will
reinforce the World Heart Federation's efforts addressing the
challenges that result from a cardiac event, such as a heart attack
or stent placement. In particular, the organizations will work
together in emphasizing the importance of a heart healthy lifestyle
and adherence to medications for acute coronary syndrome (ACS)
"We find that people who have experienced a cardiac event often
struggle to cope with the physical and emotional impact," said Pekka
Puska, President of the World Heart Federation. "This collaboration
will support patients in making the lifestyle changes that are
critical during the recovery process and beyond."
Daiichi Sankyo and Lilly will support activities stemming from
the World Heart Federation's 2009 World Heart Day, scheduled to take
place on Sunday, September 27 with a focus on workplace wellness.
Acute coronary syndrome (ACS) is an umbrella term that includes
unstable angina (chest pain) and myocardial infarction (heart
attack). ACS is ultimately the result of coronary heart disease,
which is the most severe among cardiovascular diseases.
About the World Heart Federation
The World Heart Federation is a nongovernmental organization
based in Geneva Switzerland dedicated to the prevention and control
of heart disease and stroke, with a focus on low- and middle-income
countries. It is comprised of 195 member societies of cardiology and
heart foundations from over 100 countries covering the regions of
Asia-Pacific, Europe, East Mediterranean, the Americas and Africa.
For further information visit: www.world-heart-federation.org.
About Daiichi Sankyo
A global pharma innovator, Daiichi Sankyo Co., Ltd., was
established in 2005 through the merger of two leading Japanese
pharmaceutical companies. This integration created a more robust
organization that allows for continuous development of novel drugs
that enrich the quality of life for patients around the world. Areas
of primary focus for Daiichi Sankyo's research and development are
thrombotic disorders, malignant neoplasm, diabetes mellitus, and
autoimmune disorders. Equally important to the company are
hypertension, hyperlipidemia or atherosclerosis and bacterial
infections. For more information, visit www.daiichisankyo.com.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers -- through medicines and information -- for some of the
world's most urgent medical needs.
(1) World Health Organization. Cardiovascular diseases. Fact
Sheet No. 317. February 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090331/CL90914LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )
ots Originaltext: Eli Lilly and Company
Im Internet recherchierbar: http://www.presseportal.ch
Charanjit K. Jagait, World Heart Federation, +41-22-807-03-34
(office); Carole Copeland, Eli Lilly and Company, +1-317-277-3661
(office), +1-317-610-6196 (cell); Kimberly Wix, Daiichi Sankyo,
+1-973-695-8338 (office), +1-908-656-5447 (cell) / Logo: